TEVA-ELETRIPTAN DIN 02382091
Status: Marketed
Holder: TEVA CANADA LIMITED
Molecule: ELETRIPTAN (ELETRIPTAN HYDROBROMIDE)
Available to quote
Health Canada record
| Active ingredient(s) | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 20 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N02CC06 ELETRIPTAN |
| Original market date | 20-Dec-2013 |
| Current status date | 20-Dec-2013 |
| Source | Health Canada DPD |
Establishment licence of the holder
Teva Canada Limited — licence 101810, currently licensed, last inspection rating C (2025-03-04).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ELETRIPTAN (ELETRIPTAN HYDROBROMIDE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02518015 | APO-ELETRIPTAN TABLETS | APOTEX INC | Tablet | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 20 MG | Marketed |
| 02518023 | APO-ELETRIPTAN TABLETS | APOTEX INC | Tablet | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 40 MG | Marketed |
| 02479451 | AURO-ELETRIPTAN | AURO PHARMA INC | Tablet | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 20 MG | Marketed |
| 02479478 | AURO-ELETRIPTAN | AURO PHARMA INC | Tablet | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 40 MG | Marketed |
| 02511274 | ELETRIPTAN | SANIS HEALTH INC | Tablet | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 40 MG | Marketed |
| 02511266 | ELETRIPTAN | SANIS HEALTH INC | Tablet | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 20 MG | Marketed |
| 02493683 | JAMP ELETRIPTAN | JAMP PHARMA CORPORATION | Tablet | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 20 MG | Marketed |
| 02493691 | JAMP ELETRIPTAN | JAMP PHARMA CORPORATION | Tablet | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 40 MG | Marketed |
| 02489988 | PRO-ELETRIPTAN | PRO DOC LIMITEE | Tablet | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 40 MG | Marketed |
| 02489961 | PRO-ELETRIPTAN | PRO DOC LIMITEE | Tablet | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 20 MG | Marketed |
| 02256304 | RELPAX | BGP PHARMA ULC | Tablet | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 40 MG | Marketed |
| 02256290 | RELPAX | BGP PHARMA ULC | Tablet | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 20 MG | Marketed |
| 02382105 | TEVA-ELETRIPTAN | TEVA CANADA LIMITED | Tablet | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 40 MG | Marketed |
| 02342235 | VTRS-ELETRIPTAN | MYLAN PHARMACEUTICALS ULC | Tablet | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 20 MG | Marketed |
| 02342243 | VTRS-ELETRIPTAN | MYLAN PHARMACEUTICALS ULC | Tablet | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 40 MG | Marketed |
| 02386062 | APO-ELETRIPTAN | APOTEX INC | Tablet | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 40 MG | Dormant |
| 02386054 | APO-ELETRIPTAN | APOTEX INC | Tablet | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 20 MG | Dormant |
| 02434350 | PMS-ELETRIPTAN | PHARMASCIENCE INC | Tablet | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 40 MG | Dormant |
| 02434342 | PMS-ELETRIPTAN | PHARMASCIENCE INC | Tablet | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 20 MG | Dormant |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 14287 | 2013-04-12 | Abbreviated New Drug Submission (ANDS) |